3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
116
Gastrointestinal
18
Breast
14
Thoracic
13
Head & Neck
13
Dermatologic
13
Gynecologic
10
Sarcoma
6
Lymphoid
4
CNS
3
Other solid neoplasm
2
Other
1
NET
1
Myeloid
1
Endocrine
1
Classical hematology
1
Conditions
Anemia, Refractory, with Excess of Blasts
255
Myelodysplastic Syndromes
228
Leukemia, Myeloid, Acute
228
Anemia
212
Leukemia
205
Precursor Cell Lymphoblastic Leukemia-Lymphoma
168
Leukemia, Myelomonocytic, Chronic
145
Neoplasms
142
Leukemia, Lymphocytic, Chronic, B-Cell
116
Myeloproliferative Disorders
114
Multiple Myeloma
113
Lymphoma, Non-Hodgkin
105
Thrombocytopenia
100
Lymphoma
98
Hodgkin Disease
91
Anemia, Refractory
81
Venous Thromboembolism
77
Congenital Abnormalities
77
Anemia, Aplastic
77
Primary Myelofibrosis
76
Lymphoma, Follicular
73
Leukemia, Myeloid, Chronic-Phase
70
Blast Crisis
67
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
65
Leukemia, Myeloid, Accelerated Phase
64
Lymphoma, Mantle-Cell
63
Febrile Neutropenia
62
Myelodysplastic-Myeloproliferative Diseases
58
Hematologic Neoplasms
56
Burkitt Lymphoma
56
Interventions
Rivaroxaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urologic Neoplasms
×
Classical hematology
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled